The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2024 | Recommendations for physicians treating PV: selecting between hydroxyurea and interferon
Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares her recommendations for community physicians managing patients with polycythemia vera (PV), outlining the key considerations when selecting between the two main treatment options (oral hydroxyurea and interferon). Dr Masarova emphasizes the importance of patient preference and age when selecting a therapeutic strategy. Although oral hydroxyurea is a more convenient option, clinicians should consider interferon for eligible patients due to its ability to prolong event-free survival (EFS) and prevent progression and vascular events. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research support/advisory board participation: Cogent, GSK, Morphosys, PharmaEssentia.
